- Bachelors degree in Biology- Duke University (2001)
- Doctorate of Pharmacy- University of North Carolina at Chapel Hill (2006)
- PGY-1 Pharmacy Practice Residency at the University of Texas at Tyler (2007)
- PGY-2 HIV Specialty Residency at the State University of New York at Buffalo (2008)
- STAR Health Disparities Fellowship through the University at North Texas Health Science Center at Fort Worth (2010)
I grew up in Cape Town, South Africa during most of my childhood. Having witnessed the devastating effects of AIDS on the South African population, this sparked in me a deep passion to pursue a career that encompassed care for people living with HIV (PLWH). Fortunately, I was able to build on my interests in antiretroviral pharmacology and clinical expertise in HIV through pharmacy school at UNC Chapel Hill and my PGY2 HIV Specialty residency in SUNY-Buffalo under worldwide leadership and mentoring of Drs. Angela Kashuba and Gene Morse, respectively. I then worked as a HIV clinical pharmacist in both pediatric and adult HIV populations with worldwide experts Drs. Mary Paul and Joseph Gathe for 9 years in Houston, Texas.
During the last few years of my appointment at University of Houston I became more interested in pharmacogenomics since I observed first-hand the benefits it had on some of my patients with HIV who had other medical problems such as depression. Having also worked some time as a pharmacogenomist in Houston this further gave me a greater appreciation of the field. At the University of Houston, I invested in research that focused on complementary alternative medicine such as epigallocatechin gallate (EGCG) in green tea, crofelemer and vitamin D.
After gaining excellent HIV clinical and research experience in these areas, I then accepted a position at WSU. This faculty appointment has provided numerous opportunities for expanding and sharing my teaching interests in HIV and pharmacogenomics, including special populations, pharmacology related to cardiology, renal, pulmonary, immunology, infectious diseases and oncology areas as well as a residency preparation elective. I also offer APPE rotations in HIV/pharmacogenomics academia including an annual HIV/AIDS precision medicine rotation in Cape Town, South Africa. My current research interests include education and scholarship of teaching in HIV and pharmacogenomics as well as clinical implementation of pharmacogenomics to improve treatment outcomes in both the general and HIV populations worldwide.
In my spare time I like to…
I enjoy the beauty that Washington state has to offer throughout the year, love to travel, enjoy exercising, and am a sports fanatic.
WSU gave me opportunities to broaden my teaching capacity, invest in global education, and to meet the clinical needs of the rural community.
My Favorite Quote
“Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
- PY2 Yakima Faculty of the Year Award 2019-2020
- Masters of Arts in Medical Sciences (MAMs)-Heritage University Thank You Award for Outstanding Teaching/Advising/Mentoring 2020
Rustin D. Crutchley, David M. Jacobs, Joseph Gathe, Carl Mayberry, Nataliya Bulayeva, Kevin P. Rosenblatt, and Kevin W. Garey. Assessing changes in vitamin D over 48 weeks in treatment-naïve HIV individuals starting lopinavir/ritonavir monotherapy. Current HIV Research 2020 August 27; doi: 10.2174/1570162X18666200827115615. Online ahead of print.
Crutchley RD, Min AC. Human immunodeficiency virus. In: Benavides S, Nahata MC, eds. Pediatric Pharmacotherapy. 2nd ed. Lenexa, KS: American College of Clinical Pharmacy; 2020; 749–799.
Hwang GS, Bhat R, Crutchley RD, Trivedi MV. Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes. Pharmacogenomics J. 2018; 18(2):201-208.
McCoy C, Badowski M, Sherman E, Crutchley R, Smith E, Chastain DB, and for the Society of Infectious Diseases Pharmacists. Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice. Pharmacotherapy 2018; 38(1):86-107.
Crutchley RD, Guduru RC, and Cheng AM. Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection. HIV/AIDS-Research and Palliative Care. 2016; 8:47-65.
Crutchley RD, Gathe J, Mayberry C, Trieu A, Abughosh S, Garey KW. Risk Factors for Vitamin D Deficiency in HIV-Infected Patients in the South Central United States. AIDS Res Hum Retroviruses 2012; 28(5):454-9.
Rustin D. Crutchley, Qing Ma, Adel Sulaiman, Jill Hochreitter, and Gene D. Morse. Within patient atazanavir trough concentration monitoring in HIV-1 infected patients. Journal of Pharmacy Practice 2010; 24(2):216-22.
RD Crutchley, Miller J, Garey KW. Crofelemer, a novel agent for treatment of secretory diarrhea. Ann Pharmacother 2010; 44(5):878-84.
Rezk NL, Crutchley RD, Yeh RF, Kashuba AD. Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring. Ther Drug Monit. 2006; 28(4): 517-25.
Rezk NL, Crutchley RD, Kashuba AD. Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 822(1-2): 201-208.